Buccal versus Vaginal Misoprostol Combined with a Foley Catheter among Individuals with Obesity Undergoing Induction
- 17 April 2024
- journal article
- research article
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 41 (13) , 1748-1754
Abstract
Objective Combining pharmacologic agents with mechanical ripening achieves the shortest labor duration, yet there is no clear evidence on route of drug administration in obese individuals. The use of buccal misoprostol has shown greater patient acceptance but remains understudied. Our objective was to evaluate the difference in time to delivery of buccal compared with vaginal misoprostol in combination with a Foley catheter (FC) for induction of labor (IOL) in the obese population. Study Design This was a secondary analysis of a randomized controlled trial comparing identical dosages (25 μg) of buccal and vaginal misoprostol in combination with a FC. The parent trial was an institutional review board-approved, randomized clinical trial conducted from June 2019 through January 2020. Labor management was standardized among participants. Women undergoing IOL at ≥37 weeks with a singleton gestation and cervical dilation ≤2 cm were included. Body mass index (BMI, kg/m2) was stratified. The primary outcome was time to delivery. Results A total of 215 participants were included. Demographic characteristics were similar between the three groups. Vaginal drug administration achieved a faster median time to delivery than the buccal route among patients with a body mass index greater than or equal to 30 kg/m2 (vaginal misoprostol–FC: 21.3 hours vs. buccal misoprostol–FC: 25.2 hours, p = 0.006). There was no difference in the cesarean delivery rate between the two groups. Furthermore, patients with a BMI greater than or equal to 30 kg/m2 receiving vaginal misoprostol delivered 1.2 times faster than women who received buccal misoprostol after censoring for cesarean delivery and adjusting for parity (hazard ratio: 1.2, 95% confidence interval: 1.1–1.7). There were no significant differences in maternal and neonatal outcomes. Conclusion We found that vaginal misoprostol was superior to buccal misoprostol when combined with a FC among individuals with a BMI greater than or equal to 30 kg/m2. Vaginal misoprostol should be the preferred route of drug administration for term IOL in this population. Key PointsKeywords
This publication has 24 references indexed in Scilit:
- Early vs expectant artificial rupture of membranes following Foley catheter ripening: a randomized controlled trialAmerican Journal of Obstetrics and Gynecology, 2022
- Buccal vs vaginal misoprostol combined with Foley catheter for cervical ripening at term (the BEGIN trial): a randomized controlled trialAmerican Journal of Obstetrics and Gynecology, 2021
- A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trialAmerican Journal of Obstetrics and Gynecology, 2019
- Cumulative oxytocin dose during induction of labor according to maternal body mass indexInternational Journal of Gynecology & Obstetrics, 2015
- Inhibitory effect of visfatin and leptin on human and rat myometrial contractilityLife Sciences, 2015
- Physiological, pathological and potential therapeutic roles of adipokinesDrug Discovery Today, 2012
- The effect of maternal obesity on the rate of failed induction of laborAmerican Journal of Obstetrics and Gynecology, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Adipose Tissue: The New Endocrine Organ? A Review ArticleDigestive Diseases and Sciences, 2008
- Inhibitory effect of leptin on human uterine contractility in vitroAmerican Journal of Obstetrics and Gynecology, 2006